264 related articles for article (PubMed ID: 12325070)
1. Treatment of multiple sclerosis with the pregnancy hormone estriol.
Sicotte NL; Liva SM; Klutch R; Pfeiffer P; Bouvier S; Odesa S; Wu TC; Voskuhl RR
Ann Neurol; 2002 Oct; 52(4):421-8. PubMed ID: 12325070
[TBL] [Abstract][Full Text] [Related]
2. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Bar-Or A; Vollmer T; Antel J; Arnold DL; Bodner CA; Campagnolo D; Gianettoni J; Jalili F; Kachuck N; Lapierre Y; Niino M; Oger J; Price M; Rhodes S; Robinson WH; Shi FD; Utz PJ; Valone F; Weiner L; Steinman L; Garren H
Arch Neurol; 2007 Oct; 64(10):1407-15. PubMed ID: 17698695
[TBL] [Abstract][Full Text] [Related]
3. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y; Traboulsee A; Petkau AJ; Li D
Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
5. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Soldan SS; Alvarez Retuerto AI; Sicotte NL; Voskuhl RR
J Immunol; 2003 Dec; 171(11):6267-74. PubMed ID: 14634144
[TBL] [Abstract][Full Text] [Related]
6. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
7. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
8. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
9. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
10. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
11. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study.
Zabad RK; Metz LM; Todoruk TR; Zhang Y; Mitchell JR; Yeung M; Patry DG; Bell RB; Yong VW
Mult Scler; 2007 May; 13(4):517-26. PubMed ID: 17463074
[TBL] [Abstract][Full Text] [Related]
12. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.
Garren H; Robinson WH; Krasulová E; Havrdová E; Nadj C; Selmaj K; Losy J; Nadj I; Radue EW; Kidd BA; Gianettoni J; Tersini K; Utz PJ; Valone F; Steinman L;
Ann Neurol; 2008 May; 63(5):611-20. PubMed ID: 18481290
[TBL] [Abstract][Full Text] [Related]
16. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
17. Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
Pelfrey CM; Moldovan IR; Cotleur AC; Zamor N; Rudick RA
J Neuroimmunol; 2005 Oct; 167(1-2):190-203. PubMed ID: 16046001
[TBL] [Abstract][Full Text] [Related]
18. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
Parry A; Corkill R; Blamire AM; Palace J; Narayanan S; Arnold D; Styles P; Matthews PM
J Neurol; 2003 Feb; 250(2):171-8. PubMed ID: 12574947
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.
Achiron A; Kishner I; Sarova-Pinhas I; Raz H; Faibel M; Stern Y; Lavie M; Gurevich M; Dolev M; Magalashvili D; Barak Y
Arch Neurol; 2004 Oct; 61(10):1515-20. PubMed ID: 15477504
[TBL] [Abstract][Full Text] [Related]
20. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity.
Frisullo G; Angelucci F; Caggiula M; Nociti V; Iorio R; Patanella AK; Sancricca C; Mirabella M; Tonali PA; Batocchi AP
J Neurosci Res; 2006 Oct; 84(5):1027-36. PubMed ID: 16865709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
